BDX Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $4.7 billion, up 2.6% year-over-year (FX-neutral).

Adjusted Operating Margin: 24.2%, down 110 basis points from the prior year.

Adjusted EPS: $2.90, up 3.9%, exceeding expectations.

Free Cash Flow: $1.1 billion year-to-date, significantly improved due to better working capital management.

Shareholder Returns: $2.3 billion returned, including $2 billion in share repurchases.

2Strategic Updates and Business Highlights

Leadership Change: Vitor Roque appointed as CFO, previously Interim CFO, emphasizing continuity and strategic execution.

New BD Strategy: Focus on competing, innovating, and delivering, with over 90% of the portfolio showing mid-single-digit growth.

Growth Platforms: Double-digit growth in biologic drug delivery, Advanced Patient Monitoring, PureWick, and Advanced Tissue Regeneration.

Operational Excellence: Continued implementation of BD Excellence, achieving 8% productivity gains and enhancing manufacturing efficiency.

Cost Management: Progress on a $200 million cost-out program, with $150 million already realized.

3Forward Guidance and Outlook

Full-Year Revenue Guidance: Reaffirmed low single-digit growth, with second-half revenue expected to mirror the first half.

Adjusted EPS Guidance: Increased to $12.52 to $12.72, reflecting strong first-half performance and productivity improvements.

Market Dynamics: Anticipated currency tailwind of about 120 basis points for revenue.

4Bad News, Challenges, or Points of Concern

Headwinds: Continued pressure from Alaris, vaccines, and market dynamics in China, which collectively represent less than 10% of revenue.

FDA Warning Letter: Received for the El Paso facility related to ChloraPrep and PurPrep products, leading to a temporary shipping hold while additional testing is conducted. No patient safety signals reported.

Alaris Business: Expected to contribute a 200 basis point headwind to revenue in FY 2027 due to ongoing remediation efforts.

5Notable Q&A Insights

Performance Drivers: Strong performance attributed to key growth platforms, with Alaris and vaccine dynamics noted as expected headwinds.

M&A Strategy: Focus remains on disciplined tuck-in acquisitions, with share repurchases prioritized due to perceived undervaluation.

GLP-1 Market: Continued optimism about growth, with oral GLP-1s seen as complementary rather than competitive to injectables.

Operational Focus: Emphasis on improving commercial execution and innovation, with ongoing investments in high-growth areas and a commitment to maintaining a strong balance sheet. This summary encapsulates the key points from BD's Q2 2026 earnings call, highlighting financial performance, strategic initiatives, forward guidance, challenges, and insights from the Q&A session.